CTOs on the Move

Presbyterian Medical Services

www.pmsnm.org

 
Presbyterian Medical Services (PMS) is the successor to the United Presbyterian Churchs Medical Mission work in the Southwest which began in 1901. In 1969, an independent PMS was formed as a New Mexico non-profit corporation to ensure continuation of...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.pmsnm.org
  • 1422, Paseo De Peralta
    Santa Fe, NM USA 87501
  • Phone: 800.477.7633

Executives

Name Title Contact Details

Similar Companies

Sumitomo Pharma Co.,

Sumitomo Pharma is a pharmaceutical company that develops innovative pharmaceuticals and healthcare solutions for the betterment of healthcare and fuller lives of people worldwide.

Francks Pharmacies

Francks Pharmacies is a Ocala, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Supply US

Health Supply US provides America’s leading health care facilities and first responder networks and governments with Personal Protective Equipment (PPE), Sanitizers, and COVID Testing Kits among other devices and supplies. We service government at all ...

Promius Pharma

Promius Pharma is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.